Financiere des Professionnels Fonds d investissement inc. Has $10.36 Million Stake in Pfizer Inc. $PFE

Key Points

• Financiere des Professionnels Fonds d investissement inc. increased its stake in Pfizer Inc. by 14.4%, owning 427,190 shares worth approximately $10.36 million after acquiring additional shares in the second quarter.
• Pfizer's recent earnings report revealed an EPS of $0.78, which surpassed the consensus estimate of $0.58, along with revenues of $14.65 billion, indicating a 10.3% increase year-over-year.
• The company has declared a quarterly dividend of $0.43 per share, reflecting a 7.2% dividend yield and a high payout ratio of 91.49%.

Financiere des Professionnels Fonds d investissement inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 427,190 shares of the biopharmaceutical company's stock after acquiring an additional 53,693 shares during the period. Financiere des Professionnels Fonds d investissement inc.'s holdings in Pfizer were worth $10,355,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Trust Co of the South lifted its position in Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after acquiring an additional 441 shares during the last quarter. William B. Walkup & Associates Inc. lifted its position in Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after acquiring an additional 454 shares during the last quarter. Members Trust Co raised its position in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC raised its position in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares during the last quarter. Finally, Fragasso Financial Advisors Inc raised its position in shares of Pfizer by 2.2% during the second quarter. Fragasso Financial Advisors Inc now owns 22,460 shares of the biopharmaceutical company's stock valued at $544,000 after buying an additional 480 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

PFE opened at $23.88 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company's 50 day simple moving average is $24.73 and its 200-day simple moving average is $24.25. The stock has a market capitalization of $135.77 billion, a P/E ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.